только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 18 / 20
Страница 1 / 1

Список литературы

  1. Seminario-Vidal L., Kroshinsky D., Malachowski S.J. et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults // J. Am. Acad. Dermatol. 2020. Vol. 82. N. 6. P. 1553–1567. DOI: 10.1016/j.jaad.2020.02.066. PMID: 32151629.
  2. Abe J., Mataki K., Umetsu R. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004–2013 // Allergol. Int. 2015. Vol. 64. N. 3. P. 277–279.
  3. Sekula P., Dunant A., Mockenhaupt M. et al. Comprehensive Survival Analysis of a Cohort of Patients with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis // J. Investig. Dermatol. 2013. Vol. 133. P. 1197–1204. [CrossRef] [PubMed].
  4. Micheletti R.G., Chiesa-Fuxench Z., Noe M.H. et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States // J. Invest. Dermatol. 2018. Vol. 138. N. 11. P. 2315–2321.
  5. Cadogan М. Albert Mason Stevens. Life in the Fastlane. 2021. https://litfl.com/albert-mason-stevens/.
  6. Cadogan М. Frank Chambliss Johnson. 2021. https://litfl.com/frank-chambliss-johnson/.
  7. Cadogan М. Alan Lyell. Life in the Fastlane. 2020. https://litfl.com/alan-lyell/.
  8. Maity S., Banerjee I., Sinha R. et al. Nikolsky’s sign: A pathognomic boon // J. Family Med. Prim. Care. 2020. Vol. 9. N. 2. P. 526–530. DOI: 10.4103/jfmpc.jfmpc_889_19. PMID: 32318376. PMCID: PMC7114071.
  9. Murari A., Singh K.N. Lund and Browder chart-modified versus original: a comparative study // Acute Crit. Care. 2019. Vol. 34. N. 4. P. 276–281. DOI: 10.4266/acc.2019.00647. PMID: 31795625. PMCID: PMC6895471.
  10. Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Vol. 390. Issue 10106. P. 1996–2011. DOI: 10.1016/S0140-6736(16)30378-6. PMID: 28476287.
  11. Pichler W.J. Modes of presentation of chemical neoantigens to the immune system // Toxicology. 2002. Vol. 181–182. P. 49–54. DOI: 10.1016/s0300-483x(02)00254-8. PMID: 12505284.
  12. Pichler W.J., Adam J., Watkins S. et al. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors // Int. Arch. Allergy Immunol. 2015. Vol. 168. N. 1. P. 13–24. DOI: 10.1159/000441280. PMID: 26524432.
  13. Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Dermatol. 2015. Vol. 42. N. 1. P. 42–48.
  14. Pichler W.J. Immune pathomechanism and classification of drug hypersensitivity // Allergy. 2019. Vol. 74. N. 8. P. 1457–1471. DOI: 10.1111/all.13765)
  15. Pichler W.J. The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors // World Allergy Organ J. 2008. Vol. 1. N. 6. P. 96–102. DOI: 10.1097/WOX.0b013e3181778282. PMID: 23282405. PMCID: PMC3651037.
  16. Schnyder B., Brockow K. Pathogenesis of drug allergy — current concepts and recent insights // Clin. Exp. Allergy. 2015. Vol. 45. N. 9. P. 1376–1383. DOI: 10.1111/cea.12591. PMID: 26172398.
  17. Yun J., Marcaida M.J., Eriksson K.K. et al. Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58: 01 // J. Immunol. 2014. Vol. 192. N. 7. P. 2984–2993.
  18. Pichler W.J., Beeler A., Keller M. et al. Pharmacological Interaction of Drugs with Immune Receptors: The p-i Concept // Allergol. Int. 2006. Vol. 55. N. 1. P. 17–25.
  19. Yang C.W.O., Hung S.I., Juo C.G. et al. HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2007. Vol. 120. N. 4. P. 870–877.
  20. Lerch M., Mainetti C., Terziroli Beretta-Piccoli B. et al. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis // Clin. Rev. Allergy Immunol. 2018. Vol. 54. N. 1. P. 147–176.
  21. Illing P.T., Vivian J.P., Dudek N.L. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire // Nature. 2012. Vol. 486. Issue 7404. P. 554–558.
  22. Ostrov D.A., Grant B.J., Pompeu Y.A. et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109. N. 25. P. 9959–9964.
  23. Hung S.I., Chung W.H., Liou L.B. et al. HLA–B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. P. 4134–4139.
  24. Wei C.Y., Chung W.H., Huang H.W. et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2012. Vol. 129. N. 6. P. 1562–1569.e5.
  25. Chung W.H., Pan R.Y., Chu M.T. et al. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions // J. Invest. Dermatol. 2015. Vol. 135. N. 9. P. 2237–2248.
  26. Pan R.Y., Chu M.T., Wang C.W. et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions // Nat. Commun. 2019. Vol. 10. N. 1. P. 3569.
  27. Hasegawa A., Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis // F1000Res. 2020. Vol. 9. P. F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1. PMID: 32595945. PMCID: PMC7308994.
  28. Chang W.C., Abe R., Anderson P. et al. SJS/TEN 2019: From science to translation // J. Dermatol. Sci. 2020. Vol. 98. N. 1. P. 2–12. DOI: 10.1016/j.jdermsci.2020.02.003. PMID: 32192826. PMCID: PMC7261636.
  29. Azukizawa H. Animal models of toxic epidermal necrolysis // J. Dermatol. 2011. Vol. 38. N. 3. P. 255–260. DOI: 10.1111/j.1346-8138.2010.01173.x. PMID: 21342227.
  30. Borchers A.T., Lee J.L., Naguwa S.M. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis // Autoimmun. Rev. 2008. Vol. 7. N. 8. P. 598–605. DOI: 10.1016/j.autrev.2008.06.004. PMID: 18603022.
  31. Tohyama M., Watanabe H., Murakami S. et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis // Br. J. Dermatol. 2012. Vol. 166. N. 2. P. 322–330.
  32. Correia O., Delgado L., Roujeau J.C. et al. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples // Arch. Dermatol. 2002. Vol. 138. N. 1. P. 29–32.
  33. Elmore S. Apoptosis: A Review of Programmed Cell Death // Toxicol. Pathol. 2007. Vol. 35. N. 4. P. 495–516.
  34. Lotti R., Shu E., Petrachi T. et al. Soluble Fas Ligand Is Essential for Blister Formation in Pemphigus // Front. Immunol. 2018. Vol. 9. P. 370. DOI: 10.3389/fimmu.2018.00370. PMID: 29535737. PMCID: PMC5834757.
  35. Frazzette N., Cruz A.C., Wu X. et al. Super-Resolution Imaging of Fas/CD95 Reorganization Induced by Membrane-Bound Fas Ligand Reveals Nanoscale Clustering Upstream of FADD Recruitment // Cells. 2022. Vol. 11. N. 12. P. 1908. DOI: 10.3390/cells11121908. PMID: 35741037. PMCID: PMC9221696.
  36. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Soluble Fas ligand involvement in the pathomechanisms of these diseases // J. Dermatol. Sci. 2008. Vol. 52. N. 3. P. 151–159.
  37. Stur K., Karlhofer F.M., Stingl G. Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas // J. Invest. Dermatol. 2007. Vol. 127. N. 4. P. 802–807.
  38. Morel E., Escamochero S., Cabañas R. et al. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Allergy Clin. Immunol. 2010. Vol. 125. N. 3. P. 703–710, 710.e1–710.e8. DOI: 10.1016/j.jaci.2009.10.030. PMID: 2013297.
  39. Su S.C., Mockenhaupt M., Wolkenstein P. et al. Interleukin-15 is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis // J. Invest. Dermatol. 2017. Vol. 137. N. 5. P. 1065–1073. DOI: 10.1016/j.jid.2016.11.034.
  40. Lerch M., Mainetti C., Terziroli Beretta-Piccoli B., Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis // Clin. Rev. Allergy Immunol. 2018. Vol. 54. N. 1. P. 147–176. DOI: 10.1007/s12016-017-8654-z. PMID: 29188475.
  41. Tong J., Chan J. Stevens-Johnson Syndrome Due to Influenza Vaccination // Cureus. 2020. Vol. 12. N. 7. P. e9405. DOI: 10.7759/cureus.9405.
  42. Mittmann N., Knowles S.R., Koo M. et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study // Am. J. Clin. Dermatol. 2012. Vol. 13. N. 1. P. 49–54. DOI: 10.2165/11593240-000000000-00000.
  43. Tseng J., Maurer T., Mutizwa M.M. HIV-Associated Toxic Epidermal Necrolysis at San Francisco General Hospital // J. Int. Assoc. Provid. AIDS Care. 2017. Vol. 16. N. 1. P. 37–41. DOI: 10.1177/2325957415614651.
  44. Cattelan A.M., Trevenzoli M., Sasset L. et al. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature // J. Infect. 2001. Vol. 43. N. 4. P. 246–249. DOI: 10.1053/jinf.2001.0902.
  45. Paik S., Sen S., Era N., Saha B., Tripathi S.K. Fatal Nevirapine-Induced Toxic Epidermal Necrolysis in a HIV Infected Patient // J. Clin. Diagn. Res. 2016. Vol. 10. N. 3. P. FD03-FD6. DOI: 10.7860/JCDR/2016/16360.7415).
  46. Hsu D.Y., Brieva J., Silverberg N.B., Silverberg J.I. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults // J. Invest. Dermatol. 2016. Vol. 136. N. 7. P. 1387–1397. DOI: 10.1016/j.jid.2016.03.023.
  47. Coleman E.L., Olamiju B., Leventhal J.S. The life-threatening eruptions of immune checkpoint inhibitor therapy // Clin. Dermatol. 2020. Vol. 38. N. 1. P. 94–104. DOI: 10.1016/j.clindermatol.2019.10.015. PMID: 32197753.
  48. Zhang L., Shen L., Lu Y., Xue J. Cancer immunotherapy and toxic epidermal necrolysis // BMJ Support Palliat Care. 2020. Vol. 10. N. 3. P. 314–315. DOI: 10.1136/bmjspcare-2019-002135.
  49. Maloney N.J., Ravi V., Cheng K., Bach D.Q., Worswick S. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review // Int. J. Dermatol. 2020. Vol. 59. N. 6. P. e183–e188. DOI: 10.1111/ijd.14811.
  50. Pierard-Franchimont C., Lesuisse M., Humbert P., Delvenne P., Pierard G.E. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy // Curr. Drug Saf. 2012. Vol. 7. N. 5. P. 357–360. DOI: 10.2174/157488612805076543.
  51. Narang I., Panthagani A.P., Lewis M. et al. COVID-19-induced toxic epidermal necrolysis // Clin. Exp. Dermatol. 2021. Vol. 46. N. 5. P. 927–929. DOI: 10.1111/ced.14574.
  52. Shahidi-Dadras M., Araghi F., Ahmadzadeh A. et al. TEN/SJS-like lupus erythematosus presentation complicated by COVID-19 // Dermatol. Ther. 2021. Vol. 34. N. 1. P. e14612. DOI: 10.1111/dth.14612.
  53. Tanaka A., Isei M., Kikuzawa C. et al. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA // J. Dermatol. 2021. Vol. 48. N. 3. P. e144–e145. DOI: 10.1111/1346-8138.15753.
  54. Saha M., D’Cruz A., Paul N. et al. Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: ‘Killing 2 birds with one stone’ // J. Eur. Acad. Dermatol. Venereol. 2021. Vol. 35. N. 2. P. e97–e98. DOI: 10.1111/jdv.16887).
  55. Aulakh S., Arora R., Sarangal R., Chopra D. Increased Predisposition of SJS TEN in COVID-19 Patients, Presenting as Post COVID Complication: Report of Two Cases // Indian Dermatol. Online J. 2022. Vol. 13. N. 2. P. 237–239. DOI: 10.4103/idoj.idoj_510_2.
  56. Rossi C.M., Beretta F.N., Traverso G.et al. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime // Clin. Mol. Allergy. 2020. N. 18. P. 19. DOI: 10.1186/s12948-020-00133-6.
  57. Fan W.Y., Zhai Q.R., Ma Q.B., Ge H.X. Toxic epidermal necrolysis with systemic lupus erythematosus: case report and review of the literature // Ann. Palliat. Med. 2021. N. apm-21-341. DOI: 10.21037/apm-21-341. PMID: 34412491.
  58. Ng C.Y., Chen C.B., Wu M.Y. et al. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies // J. Immunol. Res. 2018. Vol. 5376476. DOI: 10.1155/2018/5376476. PMID: 29577050. PMCID: PMC5822766.
  59. Gatson N.T., Travers J.B., Al-Hassani M. et al. Progression of toxic epidermal necrolysis after tanning bed exposure // Arch. Dermatol. 2011. Vol. 147. N. 6. P. 719–723. DOI: 10.1001/archdermatol.2011.13.
  60. Velázquez-Cárcamo E.A., Rodríguez-Chávez Y., Méndez-Flores S., Domínguez-Cherit J. Lamotrigina y su relación con el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica [Lamotrigine and its relationship with Stevens-Johnson syndrome and toxic epidermal necrolysis] // Rev. Med. Inst. Mex. Seguro Soc. 2020. Vol. 58. N. 2. P. 202–205. Spanish. DOI: 10.24875/RMIMSS.M20000018. PMID: 34101565.
  61. Mansur A.T., Aydingöz I.A. A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin // Photodermatol. Photoimmunol. Photomed. 2005. Vol. 21. N. 2. P. 100–102. DOI: 10.1111/j.1600-0781.2005.00149.x
  62. Kridin K., Brüggen M.C., Chua S.L. et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study // JAMA Dermatol. 2021. Vol. 157. N. 10. P. 1182–1190. DOI: 10.1001/jamadermatol.2021.3154. PMID: 34431984. PMCID: PMC8387938.
  63. Shanbhag S.S., Sangwan V.S., Singh A. et al. Clinical Aspects of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications in India // Front. Med. (Lausanne). 2021. N. 8. P. 643955. DOI: 10.3389/fmed.2021.643955. PMID: 34513854. PMCID: PMC8429498.
  64. Chen C.B., Abe R., Pan R.Y. et al. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity // J. Immunol. Res. 2018 F. Vol. 2018. P. 6431694. DOI: 10.1155/2018/6431694. PMID: 29651444. PMCID: PMC5830968.
  65. Ueta M. Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications // Front. Med. (Lausanne). 2021. N. 8. P. 651247. DOI: 10.3389/fmed.2021.651247. PMID: 34869401. PMCID: PMC8635481.
  66. Capule F., Tragulpiankit P., Mahasirimongkol S. et al. HLA-A*24:07 as a potential biomarker for carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Filipino patients // Pharmacogenomics. 2021. Vol. 22. N. 8. P. 465–472. DOI: 10.2217/pgs-2020-0191. Epub 2021 Apr 29. PMID: 33910375. PMCID: PMC8191649.
  67. Hasegawa A., Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis // F1000Res. 2020. Vol. 9. P. F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1.
  68. Li X., Yu K., Mei S. et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies // Drug Res. (Stuttg). 2015. Vol. 65. N. 2. P. 107–111. DOI: 10.1055/s-0034-1375684.
  69. Tangamornsuksan W., Chaiyakunapruk N., Somkrua R. et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis // JAMA Dermatol. 2013. Vol. 149. N. 9. P. 1025–1032. DOI: 10.1001/jamadermatol.2013.4114.
  70. Wang Q., Sun S., Xie M. et al. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis // Epilepsy Res. 2017. Vol. 135. P. 19–28. DOI: 10.1016/j.eplepsyres.2017.05.015).
  71. Nicoletti P., Barrett S., McEvoy L. et al. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions // Clin. Pharmacol. Ther. 2019. Vol. 106. N. 5. P. 1028–1036. DOI: 10.1002/cpt.1493. PMID: 31066027. PMCID: PMC7156285.
  72. Shi Y.W., Min F.L., Zhou D. et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions // Neurology. 2017. Vol. 88. N. 23. P. 2183–2191. DOI: 10.1212/WNL.0000000000004008.
  73. Yu K.H., Yu C.Y., Fang Y.F. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis // Int. J. Rheum. Dis. 2017. Vol. 20. N. 9. P. 1057–1071. DOI: 10.1111/1756-185X.13143. PMID: 28857441.
  74. Small C.B., Margolis D.A., Shaefer M.S., Ross L.L. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects // BMC Infect. Dis. 2017. Vol. 17. N. 1. P. 256. DOI: 10.1186/s12879-017-2331-y. PMID: 28399804. PMCID: PMC5387336.
  75. Tempark T., Satapornpong P., Rerknimitr P. et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population // Pharmacogenet. Genomics. 2017. Vol. 27. N. 12. P. 429–437. DOI: 10.1097/FPC.0000000000000306.
  76. Ko T.M., Chung W.H., Wei C.Y. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2011. Vol. 128. N. 6. P. 1266–1276.e11. DOI: 10.1016/j.jaci.2011.08.013.
  77. Manuyakorn W., Siripool K., Kamchaisatian W. et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children // Pediatr. Allergy Immunol. 2013. Vol. 24. N. 3. P. 299–303. DOI: 10.1111/pai.12058).
  78. Bastuji-Garin S., Rzany B., Stern R.S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme // Arch. Dermatol. 1993. Vol. 129. P. 92e6.
  79. Creamer D., Walsh S.A., Dziewulski P. et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 // Br. J. Dermatol. 2016. Vol. 174. N. 6. P. 1194–1227. DOI: 10.1111/bjd.14530. PMID: 27317286.
  80. Auquier-Dunant A., Mockenhaupt M., Naldi L. et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study // Arch. Dermatol. 2002. Vol. 138. P. 1019–1024.
  81. Copaescu A.M., Trublano J.A. The assessment of severe cutaneous adverse drug reactions // Aust Prescr. 2022. Vol. 45. N. 2. P. 43–48. DOI: 10.18773/austprescr.2022.010. Epub 2022 Apr 1. PMID: 35592375. PMCID: PMC908193.
  82. Harman K.E., Brown D., Exton L.S. et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris // Br. J. Dermatol. 2017. Vol. 177. P. 1170–1201.
  83. Melchionda V., Harman K.E. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management // Clin. Exp. Dermatol. 2019. Vol. 44. N. 7. P. 740–746. DOI: 10.1111/ced.14041. PMID: 31378971.
  84. Broussard K.C., Leung T.G., Moradi A., Thorne J.E., Fine J.D. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica // Clin. Dermatol. 2016. Vol. 34. N. 2. P. 205–213. DOI: 10.1016/j.clindermatol.2015.11.006.
  85. Parker S.R., MacKelfresh J. Autoimmune blistering diseases in the elderly // Clin. Dermatol. 2011. Vol. 29. N. 1. P. 69–79. DOI: 10.1016/j.clindermatol.2010.07. 010.
  86. Jascholt I., Lai O., Zillikens D., Kasperkiewicz M. Periodontitis in oral pemphigus and pemphigoid: a systematic review of published studies // J. Am. Acad. Dermatol. 2017. Vol. 76. N. 5. P. 975–978. DOI: 10.1016/j.jaad.2016.10.028.
  87. Barea-Jiménez N., Calero J., Molina-Negrón D., López Del-Valle L.M. Treatment for oral lesions in pediatric patients with Stevens-Johnson’s syndrome: A case report and literature review // Int. J. Paediatr Dent. 2020. Vol. 30. N. 4. P. 489–496. DOI: 10.1111/ipd.12615. PMID: 31923328.
  88. Ramos-e-Silva M., Ferreira A., Jacques C. Oral involvement in autoimmune bullous diseases // Clin. Dermatol. 2011. Vol. 29. N. 4. P. 443–454. DOI: 10.1016/j. clindermatol.2011.01.015.
  89. Kasperkiewicz M., Ellebrecht C.T., Takahashi H. et al. Pemphigus // Nat. Rev. Dis. Primers 2017. Vol. 3. P. 17026. DOI: 10.1038/ nrdp.2017.26.
  90. Amber K.T., Valdebran M., Grando S.A. Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus // Autoimmun. Rev. 2018. Vol. 17. N. 10. P. 1002–1010. DOI: 10.1016/j.autrev.2018. 04.008.
  91. Miyamoto D., Santi C.G., Aoki V., Maruta C.W. Bullous pemphigoid // An. Bras. Dermatol. 2019. Vol. 94. N. 2. P. 133–146. DOI: 10.1590/abd1806-4841.20199007. PMID: 31090818. PMCID: PMC6486083.
  92. Di Zenzo G., Marazza G., Borradori L. Bullous pemphigoid: physiopathology, clinical features and management // Adv. Dermatol. 2007. Vol. 23. P. 257–288.
  93. Lamb P.M., Abell E., Tharp M., Frye R., Deng J.S. Prodromal bullous pemphigoid // Int. J. Dermatol. 2006. Vol. 45. P. 209–214.
  94. Bağcı I.S., Horváth O.N., Ruzicka T., Sárdy M. Bullous pemphigoid // Autoimmun. Rev. 2017. Vol. 16. N. 5. P. 445–455. DOI: 10.1016/j.autrev.2017.03.010. PMID: 28286109.
  95. Tirado-Sánchez A., Bonifaz A. Paraneoplastic Pemphigus. A Life-Threatening Autoimmune Blistering Disease // Actas Dermosifiliogr. 2017. Vol. 108. N. 10. P. 902–910. English, Spanish. DOI: 10.1016/j.ad.2017.04.024. PMID: 28801011.
  96. Duan L., Chen L., Zhong S. et al. Treatment of Bullous Systemic Lupus Erythematosus // J. Immunol. Res. 2015. Vol. 2015. P. 167064. DOI: 10.1155/2015/167064. PMID: 26090480. PMCID: PMC4451988.
  97. Rutnin S., Chanprapaph K. Vesiculobullous diseases in relation to lupus erythematosus // Clin. Cosmet. Investig. Dermatol. 2019. Vol. 12. P. 653–667. DOI: 10.2147/CCID.S220906. PMID: 31564947. PMCID: PMC6732903.
  98. Lammer J., Hein R., Roenneberg S. et al. Drug-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature // Acta Derm. Venereol. 2019. Vol. 99. N. 6. P. 508–515. DOI: 10.2340/00015555-3154. PMID: 30809685.
  99. Patel S., John A.M., Handler M.Z., Schwartz R.A. Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption // Am. J. Clin. Dermatol. 2020. Vol. 21. N. 3. P. 393–399. DOI: 10.1007/s40257-020-00505-3. PMID: 32002848.
  100. Abate M.S., Battle L.R., Emerson A.N. et al. Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know // Arch. Pathol. Lab. Med. 2019. Vol. 143. N. 8. P. 919–942. DOI: 10.5858/arpa.2018-0239-RA. PMID: 30785787.
  101. Zeiser R., Blazar B.R. Acute Graft-versus-Host Disease Biology, Prevention and Therapy // N. Engl. J. Med. 2017. Vol. 377. N. 22. P. 2167–2179. DOI: 10.1056/NEJMra1609337.
  102. Szatkowski J., Schwartz R.A. Acute generalized exanthematous pustulosis (AGEP): A review and update // J. Am. Acad. Dermatol. 2015. Vol. 73. N. 5. P. 843–848. DOI: 10.1016/j.jaad.2015.07.017. PMID: 26354880.
  103. Gonçalves R., Gata L., Brett A. Mycoplasma pneumoniae-associated mucositis // BMJ Case Rep. 2021. Vol. 14. N. 4. P. e239086. DOI: 10.1136/bcr-2020-239086. PMID: 33858884. PMCID: PMC8054042.
  104. Abela C., Hartmann C.E., De Leo A. et al. Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm // J. Plast. Reconstr. Aesthet. Surg. 2014. Vol. 67. N. 8. P. 1026–1032. DOI: 10.1016/j.bjps.2014.04.003. PMID: 24860933.
  105. Heng J.S., Malik N., Joshi N. et al. Severity of acute ocular involvement is independently associated with time to resolution of ocular disease in toxic epidermal necrolysis patients // Br. J. Opthalmol. 2015. Vol. 99. N. 2. P. 251–254.
  106. Gueudry J., Roujeau J.C., Binaghi M. et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis // Arch. Dermatol. 2009. Vol. 145. N. 2. P. 157–162.
  107. Lopez-Garcia J.S., Rivas Jara L., Garcia-Lozano C.I. et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis // Ophthalmology. 2011. Vol. 118. N. 2. P. 265–271.
  108. Meneux E., Wolkenstein P., Haddad B. et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases // Obstet. Gynecol.1998. Vol. 91. N. 2. P. 283–287.
  109. Van Batavia J.P., Chu D.I., Long C.J. et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Pediatr. Urol. 2017. Vol. 13. N. 5. P. 490.e1–490.e7.
  110. Boyraz G., Basaran D., Salman M.C. et al. Vaginal reconstruction for vaginal obliteration secondary to Stevens Johnson syndrome: a case report and review of literature // Oman Med. J. 2017. Vol. 32. N. 5. P. 436–439.
  111. Kaser D.J., Reichman D.E., Laufer M.R. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis // Rev. Obstetr. Gynecol. 2011. Vol. 4. N. 2. P. 81–85.
  112. Lee H.Y., Walsh S.A., Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up // Br. J. Dermatol. 2017. Vol. 177. N. 4. P. 924–935.
  113. Saeed H., Mantagos I.S., Chodosh J. Complications of Stevens-Johnson syndrome beyond the eye and skin // Burns. 2016. Vol. 42. N. 1. P. 20–27.
  114. Reddy R.B., Shekar P.C., Chandra K.L., Aravind R. Oral lesions associated with nevirapine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of 10 cases // J. Oral. Maxillofac. Pathol. 2013. Vol. 17. N. 3. P. 431–435.
  115. Sedghizadeh P.P., Kumar S.K., Gorur A., Mastin C., Boros A.L. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention // Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2008. Vol. 105. N. 4. P. e29–e33.
  116. Weinkle A., Pettit C., Jani A. et al. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation — a retrospective chart review // J. Am. Acad. Dermatol. 2019. Vol. 81. N. 3. P. 749–757.
  117. de Prost N., Ingen-Housz-Oro S., Duong T. et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures // Medicine. 2010. Vol. 89. N. 1. P. 28–36.
  118. Kim H.I., Kim S.W., Park G.Y. et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients // Korean J. Intern. Med. 2012. Vol. 27. N. 2. P. 203–210.
  119. Shanbhag S.S., Chodosh J., Fathy C. et al. Multidisciplinary care in Stevens-Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11: 2040622319894469. DOI: 10.1177/2040622319894469. PMID: 32523661. PMCID: PMC7236394.
  120. Ducic I., Shalom A., Rising W. et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited // Plast. Reconstr. Surg. 2002. Vol. 110. P. 768–773.
  121. Noe M.H., Rosenbach M., Hubbard R.A. et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10 // JAMA Dermatol. 2019. Vol. 155. N. 4. P. 448–454. DOI: 10.1001/jamadermatol.2018.5605. PMID: 30840032. PMCID: PMC6459085.
  122. Bastuji-Garin S., Fouchard N., Bertocchi M. et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis // J. Invest. Dermatol. 2000. Vol. 115. N. 2. P. 149–153. DOI: 10.1046/j.1523-1747.2000.00061.x. PMID: 10951229.
  123. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: A severity of disease classification system // Crit. Care Med. 1985. Vol. 13. P. 818–829.
  124. Marshall J.C., Cook D.J., Christou N.V. et al. Multiple Organ Dysfunction Score: a reliable descriptor of a complex clinical outcome // Crit. Care Med. 1995. Vol. 23. P. 1638–1652.
  125. Schulz J.T., Sheridan R.L., Ryan C.M. et al. A 10-year experience with toxic epidermal necrolysis // J. Burn. Care Rehabil. 2000. Vol. 21. P. 199e204.
  126. McGee T., Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center // Plast. Reconstr. Surg. 1998. Vol. 102. P. 1018e22.
  127. Valeyrie-Allanore L., Ingen-Housz-Oro S., Chosidow O., Wolkenstein P. French referral center management of Stevense Johnson syndrome/toxic epidermal necrolysis // Dermatol. Sin. 2013. Vol. 31. N. 4. P. 191–195.
  128. Herndon D.N. Mediators of metabolism // J. Trauma 1981. Vol. 21. P. 701e5.
  129. Herndon D.N., Tompkins R.G. Support of the metabolic response to burn injury // Lancet 2004. Vol. 363. Issue 1895. P. e902.
  130. Arnold M., Yanez C., Yanez B. Wound Healing in the Long-Term Acute Care Setting Using an Air Fluidized Therapy/Continuous Low-Pressure Therapeutic Bed: A Multiple Case Series // J. Wound Ostomy Continence Nurs. 2020. Vol. 47. N. 3. P. 284–290. DOI: 10.1097/WON.0000000000000646. PMID: 32384532.
  131. Winters W.D. A new perspective of microbial survival and dissemination in a prospectively contaminated air-fluidized bed model // Am. J. Infect. Control. 1990. Vol. 18. N. 5. P. 307–315. DOI: 10.1016/0196-6553(90)90230-p. PMID: 2123611.
  132. Papp A., Sikora S., Evans M. et al. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results // Burns. 2018. Vol. 44. N. 4. P. 807–815. DOI: 10.1016/j.burns.2017.10.022. PMID: 29627131.
  133. Paquet P., Piérard G.E. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN) // Exp. Opin.Pharmacother. 2010. Vol. 11. N. 15. P. 2447–2458. DOI: 10.1517/14656566.2010.51558.
  134. Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Vol. 390. Issue 10106. P. 1996–2011. DOI: 10.1016/S0140-6736(16)30378-6. PMID: 28476287.
  135. Whiteley I., Sinclair G., Lyons A.M., Riccardi R. A retrospective review of outcomes using a fecal management system in acute care patients // Ostomy Wound Manage. 2014. Vol. 60. N. 12. P. 37–43. PMID: 25485551.
  136. Charlton O.A., Harris V., Phan K. et al.Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care (New Rochelle). 2020. Vol. 9. N. 7. P. 426–439. DOI: 10.1089/wound.2019.0977. PMID: 32520664. PMCID: PMC7307670.
  137. Noe M.H., Micheletti R.G. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis // Clin. Dermatol. 2020. Vol. 38. N. 6. P. 607–612. DOI: 10.1016/j.clindermatol.2020.06.016. PMID: 33341195.
  138. Choi H., Castillo B., Seminario-Vidal L. Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series // Int. Wound J. 2018. Vol. 15. N. 6. P. 1049–1051. DOI: 10.1111/iwj.12938. PMID: 29893032. PMCID: PMC7949585.
  139. Lindford A.J., Kaartinen I.S., Virolainen S., Vuola J. Comparison of Suprathel® and allograft skin in the treatment of a severe case of toxic epidermal necrolysis // Burns. 2011. Vol. 37. N. 7. P. e67–72. DOI: 10.1016/j.burns.2011.07.015. PMID: 21852045.
  140. Lindford A., Vuola J. Re: Toxic epidermal necrolysis (TEN): The Chelsea and Westminster hospital wound management algorithm // J. Plast. Reconstr. Aesthet. Surg. 2015. Vol. 68. N. 2. P. 288–289. DOI: 10.1016/j.bjps.2014.09.031. PMID: 25282634.
  141. Pfurtscheller K., Zobel G., Roedl S., Trop M. Use of Suprathel dressing in a young infant with TEN // Pediatr. Dermatol. 2008. Vol. 25. N. 5. P. 541–543. DOI: 10.1111/j.1525–1470.2008.00766.x. PMID: 18950395.
  142. Solanki N.S., Nowak K.M., Mackie I.P., Greenwood J.E. Using biobrane: techniques to make life easier // Eplasty. 2010. Vol. 10. P. e70. PMID: 21187941. PMCID: PMC3008156.
  143. Dillon C.K., Lloyd M.S., Dzeiwulski P. Accurate debridement of toxic epidermal necrolysis using Versajet // Burns. 2010. Vol. 36. N. 4. P. 581–584. DOI: 10.1016/j.burns.2008.12.011. PMID: 19423228.
  144. Mahar P.D., Wasiak J., Hii B. et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres // Burns 2014. Vol. 40. P. 1245e54.
  145. Lee H.Y. Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need // J. Am. Acad. Dermatol. 2018. Vol. 79. N. 4. P. e87–e88. DOI: 10.1016/j.jaad.2018.05.1258. PMID: 29913262.
  146. Koh H.K., Chai Z.T., Tay H.W. et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients // J. Am. Acad. Dermatol. 2019. Vol. 81. N. 3. P. 686–693.
  147. Cartotto R. Burn center care of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // Clin. Plast. Surg. 2017. Vol. 44. N. 3. P. 583–595.
  148. Bequignon E., Duong T.A., Sbidian E. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission // JAMA Dermatol. 2015. Vol. 151. N. 3. P. 302–307.
  149. Oh S.J., Kwon H.I., Moon S.H. et al. Toxic epidermal necrolysis with isolated neutropenia related to the use of levetiracetam // J. Dermatol. 2016. Vol. 43. N. 8. P. 969–971.
  150. Mahajan R., Kanwar A.J. Use of granulocyte colony-stimulating factor in the treatment of toxic epidermal necrolysise experience with 3 patients // Skinmed. 2013. Vol. 11. N. 5. P. 269–271.
  151. Valeyrie-Allanore L., Ingen-Housz-Oro S., Colin A. et al. Pain management in Stevens-Johnson syndrome, toxic epidermal necrolysis and other blistering diseases // Ann. Dermatol. Venereol. 2011. Vol. 138: 694–697. P. quiz 2–3, 8.
  152. Jennes S., Pierard G.E., Paquet P. Deciphering supportive treatment strategies for toxic epidermal necrolysis // Curr. Drug. Saf. 2012. Vol. 7. P. 361–366.
  153. Kohanim S., Palioura S, Saeed H.N. et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis-a comprehensive review and guide to therapy. II. Ophthalmic disease // Ocul. Surf. 2016. Vol. 14. N. 2. P. 168–188.
  154. Sotozono C., Ueta M, Koizumi N. et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications // Ophthalmology. 2009. Vol. 116. N. 4. P. 685–690.
  155. Saeed H.N., Chodosh J. Ocular manifestations of Stevens-Johnson syndrome and their management // Curr. Opin. Ophthalmol. 2016. Vol. 27. N. 6. P. 522–529.
  156. Ciralsky J.B., Sippel K.C., Gregory D.G. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis // Curr. Opin. Ophthalmol. 2013. Vol. 24. N. 4. P. 321–328.
  157. Agrawal A., Pratap V.B. Amniotic membrane transplantation (AMT) without the use of sutures/fibrin glue // Nepal J. Ophthalmol. 2015. Vol. 7. N. 14. P. 173–177.
  158. Kim M.K., Yoon K.C., Yoon S.H., Seo K.Y. Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea // Front. Med. (Lausanne). 2021. Vol. 8. P. 640360. DOI: 10.3389/fmed.2021.640360. PMID: 33693020. PMCID: PMC7937613.
  159. Ma K.N., Thanos A., Chodosh J., Shah A.S., Mantagos I.S. A novel technique for amniotic membrane transplantation in patients with acute Stevens-Johnson syndrome // Ocul. Surf. 2016. Vol. 14. N. 1. P. 31–36.
  160. Sedghizadeh P.P., Kumar S.K., Gorur A. et al. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention // Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2008. Vol. 105. P. e29e33.
  161. Roujeau J.C., Phlippoteau C., Koso M. et al. Sjo¨gren-like syndrome after drug-induced toxic epidermal necrolysis // Lancet 1985. Vol. 1: 609e11.
  162. Shazib M.A., Muhlbauer J., Schweiker R., Li S., Cutler C., Treister N. Long-term utilization patterns of topical therapy and clinical outcomes of oral chronic graft-versus-host disease // Biol. Blood Marrow Transplant. 2020. Vol. 26. N. 2. P. 373–379.
  163. Rugo H.S., Seneviratne L., Beck J.T. et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial // Lancet Oncol. 2017. Vol. 18. N. 5. P. 654–662.
  164. Sibaud V., Eid C., Belum V.R. et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings // J. Eur. Acad. Dermatol. Venereol. 2017. Vol. 31. N. 10. P. e464–e469.
  165. Campbell L., Emmerson E., Davies F. et al. Estrogen promotes cutaneous wound healing via estrogen receptor beta independent of its antiinflammatory activities // J. Exp. Med. 2010. Vol. 207. N. 9. P. 1825–1833.
  166. Van Batavia J.P., Chu D.I., Long C.J., Jen M., Canning D.A., Weiss D.A. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Pediatr. Urol. 2017. Vol. 13. N. 5. P. 490.e1–490.e7.
  167. Buchan A., Merideth M.A., Childs R.W., Stratton P. Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos // BMJ Case Rep. 2018.
  168. Ching J.A., Kuykendall L.V., Troy J.S., Smith D.J. Jr. Estrogen treatment of acetic acid burns to the vagina, cervix, and perineum: a case report and review of the literature // J. Burn. Care Res. 2014. Vol. 35. N. 5. P. e368–e371.
  169. Shanbhag S.S., Chodosh J., Fathy C. et al. Multidiscipli-nary care in Stevens-Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11. P. 2040622319894469. DOI: 10.1177/2040622319894469. PMID: 32523661. PMCID: PMC7236394.
  170. Shiga S., Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? // J. Burn. Care Res. 2010. Vol. 31. N. 1. P. 100–104.
  171. Namdar T., von Wild T., Siemers F. et al. Does hypernatremia impact mortality in toxic epidermal necrolysis? // Ger. Med. Sci. 2010. Vol. 8. P. Doc30.
  172. Schwartz R.A., McDonough P.H., Lee B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment // J. Am. Acad. Dermatol. 2013. Vol. 69. N. 2. P. 187.e1–187.e16. quiz 203–204.
  173. Schneider J.A., Cohen P.R. Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Am. Acad. Dermatol. 2017. Vol. 77. N. 4. P. e117.
  174. Gupta L.K., Martin A.M., Agarwal N. et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective // Indian J. Dermatol. Venereo.l Leprol. 2016. Vol. 82. N. 6. P. 603–625.
  175. Jennes S., Pierard G.E., Paquet P. Deciphering supportive treatment strategies for toxic epidermal necrolysis // Curr. Drug Saf. 2012. Vol. 7. N. 5. P. 361–366. DOI: 10.2174/157488612805076570. PMID: 23373547.
  176. Stoecklin P., Delodder F., Pantet O., Berger M.M. Moderate glycemic control safe in critically ill adult burn patients: a 15 year cohort study // Burns. 2016. Vol. 42. N. 1. P. 63–70.
  177. Beck A., Cooney R, Gamelli R.L., Mosier M.J. Predicting mechanical ventilation and mortality: early and late indicators in Steven-Johnson syndrome and toxic epidermal necrolysis // J. Burn. Care Res. 2016. Vol. 37. N. 1. P. e47–e55.
  178. de Prost N., Mekontso-Dessap A., Valeyrie-Allanore L. et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation // Crit. Care Med. 2014. Vol. 42. N. 1. P. 118–128.
  179. Williams R., Hodge J., Ingram W. Indications for intubation and early tracheostomy in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // Am. J. Surg. 2016. Vol. 211. N. 4. P. 684–688.e1.
  180. Brower R.G., Matthay M.A., Morris A. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome // N. Engl. J. Med. 2000. Vol. 342. N. 18. P. 1301–1308.
  181. Halebian P.H., Corder V.J., Madden M.R., Finklestein J.L., Shires G.T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids // Ann. Surg. 1986. Vol. 204. P. 503–512.
  182. Michaels B., del Rosso J.Q. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome a review of past and current opinions // J. Clin. Aesthetic Dermatol. 2009. Vol. 2. P. 51.
  183. Workswick S., Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options // Dermatol. Ther. 2011. Vol. 24. P. 207–218.
  184. Zimmermann S., Sekula P., Venhoff M. et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis // JAMA Dermatol. 2017. Vol. 153. P. 514–522. [CrossRef] [PubMed].
  185. Kardaun S.H., Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis // Acta Derm. Venereol. 2007. Vol. 87. P. 144–148.
  186. McPherson T., Exton L.S., Biswas S. et al. British Association of Dermatologists’ guide-lines for the management of Stevens–Johnson syndrome/Toxic Epidermal Necrolysis in children and young people // Br. J. Dermatol. 2019. Vol. 181. P. 37–54. [CrossRef] [PubMed].
  187. Lee H.Y., Lim Y.L., Thirumoorthy T. et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre // Br. J. Dermatol. 2013. Vol. 169. P. 1304–1309.
  188. Yang L., Shou Y.H., Li F. et al. Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China // Front. Pharmacol. 2022. Vol. 12. P. 750173. DOI: 10.3389/fphar.2021.750173. PMID: 35115922. PMCID: PMC8804212.
  189. Schneck J., Fagot J.P., Sekula P. et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study // J. Am. Acad. Dermatol. 2008. Vol. 58. P. 33–40.
  190. Murphy J.T., Purdue G.F., Hunt J.L. Toxic epidermal necrolysis // J. Burn. Care Rehabil. 1997. Vol. 18. P. 417–420.
  191. Tsai T.Y., Huang I.H., Chao Y.C. et al. Treating Toxic Epidermal Necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis // J. Am. Acad. Dermatol. 2021. Vol. 84. P. 390–397. [CrossRef].
  192. Fernandez A.P., Kerdel F.A. The use of i.v. IG therapy in dermatology // Dermatol. Ther. 2007. Vol. 20. P. 288–305. [CrossRef] [PubMed].
  193. Zhu Q.Y., Ma L., Luo X.Q., Huang H.Y. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China // J. Burn. Care Res. 2012. Vol. 33. P. e295–308.
  194. Narita Y.M., Hirahara K., Mizukawa Y. et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? // J. Dermatol. 2011. Vol. 38. P. 236–245.
  195. Kuprash D.V., Boitchenko V.E., Yarovinsky F.O. et al. Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells // Blood 2002. Vol. 100. P. 1721–1727.
  196. Valeyrie-Allanore L., Wolkenstein P., Brochard L. et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis // Br. J. Dermatol. 2010. Vol. 163. P. 847–853.
  197. Arevalo J.M., Lorente J.A., Gonzalez-Herrada C., Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporine A // J. Trauma 2000. Vol. 48. P. 473–478.
  198. Singh G.K., Chatterjee M., Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid // Indian J. Dermatol. Venereol. Leprol.2013. Vol. 79. P. 686–692.
  199. Kirchhof M.G., Miliszewski M.A., Sikora S. et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine // J. Am. Acad. Dermatol. 2014. Vol. 71. P. 941–947.
  200. Zaki I., Patel S., Reed R. et al. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporine // Br. J. Dermatol 1995. Vol. 133. P. 337–338.
  201. Zhang S., Tang S. et al. Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: A systemic review // J. Dermatol. Treat. 2020. Vol. 31. P. 66–73. [CrossRef] [PubMed].
  202. Wang C.W., Yang L.Y., Chen C.B. et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions // J. Clin. Investig. 2018. Vol. 128. P. 985–996. [CrossRef].
  203. Jarrett P., Rademaker M., Havill J. et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor // Clin. Exp. Dermatol. 1997. Vol. 22. P. 146–147.
  204. Winfred R.I., Nanda S., Horvath G. et al. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor // South Med. J. 1999. Vol. 92. P. 918–920.
  205. Robak E., Robak T., Gora-Tybor J. et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF // J. Med. 2001. Vol. 32. P. 31–39.
  206. Han F., Zhang J., Guo Q. et al. Successful treatment of Toxic Epidermal Necrolysis using plasmapheresis: A prospective observational study // J. Crit. Care 2017. Vol. 42. P. 65–68. [CrossRef] [PubMed]
  207. Frantz R., Huang S., Are A., Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management // Medicina (Kaunas). 2021 Aug 28. Vol. 57. N. 9. P. 895. DOI: 10.3390/medicina57090895. PMID: 34577817. PMCID: PMC8472007.
  208. Butt T.F., Cox A.R., Lewis H. et al. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK // Drug Saf 2011. Vol. 34. P. 319e28.
  209. Sotozono C., Ang L.P., Koizumi N. et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome // Ophthalmology 2007. Vol. 114. P. 1294e302.

Для продолжения работы требуется вход / регистрация